The antibody-drug conjugate sacituzumab tirumotecan combo slowed advanced lung cancer
- The antibody-drug conjugate sacituzumab tirumotecan combo slowed advanced lung cancer
- PD-1 immunotherapy studied after surgery for several cancers
- AI tool improved predictions from cancer tissue slides
- A blood test predicted survival with prostate cancer radioligand treatment
The antibody-drug conjugate sacituzumab tirumotecan combo slowed advanced lung cancer
People with newly diagnosed advanced lung cancer received the antibody-drug conjugate sacituzumab tirumotecan with the immunotherapy pembrolizumab. The cancer took a median 15 months to grow, versus 5.7 months with chemotherapy and pembrolizumab.
Why it matters. People with advanced lung cancer without targetable changes may have more time before their cancer grows with this combination. Results from a large final-stage trial like this decide approvals.
Cancer Discovery, 14 Nov 2026 · Phase III human clinical trial Worth sharing · Share on X · Email a friendPD-1 immunotherapy studied after surgery for several cancers
People with several types of early-stage cancer received six months of PD-1 immunotherapy with pembrolizumab after a blood test found signs of leftover cancer. The test became negative in 11 of 13 people, but five had a recurrence.
“These findings provide evidence that ctDNA-guided adjuvant therapy (given after surgery) may offer clinical benefit in dMMR tumors regardless of tissue of origin.”
Why it matters. People with several types of cancer after surgery may one day get immunotherapy guided by a blood test for leftover cancer. A larger trial usually comes before approval.
Annals of Oncology, 13 Nov 2026 · Phase II human clinical trial | 184 patients Worth sharing · Share on X · Email a friendAI tool improved predictions from cancer tissue slides
Researchers tested Hist2Prot, an artificial intelligence tool that predicts protein patterns from routine cancer slides, across seven patient groups. Its predictions improved estimates of cancer outcomes and response to immunotherapy for 1,774 patients.
Why it matters. People with cancer may get better predictions about how their disease will progress and whether immunotherapy may help. It studied patient records rather than testing a treatment.
Nature Cancer, 13 Nov 2026 · Human observational study | 1,774 patientsA blood test predicted survival with prostate cancer radioligand treatment
Researchers reviewed 501 people with advanced prostate cancer who received radioligand treatment after taxane therapy. A ratio of two types of blood cells above 3 predicted poorer survival, especially when it stayed high at the next treatment cycle.
“NLR > 3 is an adverse prognostic factor in patients receiving LuPSMA, and early NLR dynamics may be helpful in identifying patients who require closer disease monitoring during therapy.”
Why it matters. People with advanced prostate cancer receiving radioligand treatment may get closer monitoring if their blood test ratio stays high. It studied patient records rather than testing a treatment.
Prostate Cancer and Prostatic Diseases, 14 Nov 2026 · Human observational study | 501 patientsDeals and stopped trials
- Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)Terminated · Phase II · Merck Sharp & Dohme LLC · Reason given: Business Reasons
Worth watching
- The antibody-drug conjugate sacituzumab tirumotecan delayed lung cancer growthPeople with newly diagnosed advanced lung cancer received the antibody-drug conjugate sacituzumab tirumotecan and the immunotherapy pembrolizumab. Their cancer took 15 months to grow, compared with 5.7 months with chemotherapy and pembrolizumab.
- Immunotherapy cleared tumor DNA in several cancers after surgeryIn a phase II trial, people with several mismatch repair-deficient cancers received six months of the PD-1 immunotherapy pembrolizumab after surgery. Tumor DNA cleared from the blood in 11 of 13 people treated.
- Gene patterns predicted treatment resistance in breast cancerResearchers studied pretreatment samples from 987 people with stage II to III breast cancer in a phase II trial. In a validation group, the paclitaxel gene pattern identified 0.88 of people with poor response.
- Long-term trends and COVID-19 pandemic–era changes in the incidence of cancers with established screening strategies in the United States: a population-based SEER studyResearch finding, Scientific Reports, 15 Nov 2026